Measles-mumps-rubella vaccine that is given in the second year of life is associated with an increased risk of immune thrombocytopenia purpura. - GreenMedInfo Summary
Abstract Title:
Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
Abstract Source:
Pediatrics. 2008 Mar;121(3):e687-92. PMID: 18310189
Article Affiliation:
Department of Preventive Medicine, Kaiser Pemanente Colorado, Denver, CO 80231, USA. [email protected]
Abstract:
BACKGROUND: The measles-mumps-rubella vaccine has been associated with immune thrombocytopenia purpura in 2 small studies. METHODS: By using the Vaccine Safety Datalink, we identified measles-mumps-rubella-vaccinated children aged 1 to 18. A case of immune thrombocytopenia purpura was defined as a patient with a platelet count of
Article Published Date : Mar 01, 2008
Study Type : Human Study
Additional Links
Diseases : Purpura: Thrombocytopenic : CK(286) : AC(47), Thrombocytopenia : CK(287) : AC(47), Vaccine-induced Toxicity : CK(2918) : AC(559)
Anti Therapeutic Actions : Vaccination: All : CK(12698) : AC(1348), Vaccination: Mumps-Measles-Rubella (MMR) : CK(832) : AC(116)
